Abstract
α-Synuclein aggregation into fibrils is associated with the pathogenesis of Parkinson's disease (PD). Li et al. provide strong evidence that rifampicin interacts with α-synuclein and inhibits its fibrillization [1]. Rifampicin could be a promising candidate for therapeutic application for PD.
Original language | English |
---|---|
Pages (from-to) | 1476-1478 |
Number of pages | 3 |
Journal | Chemistry and Biology |
Volume | 11 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2004 |
Externally published | Yes |